Immunological effects of a low-dose cytarabine, aclarubicin and granulocyte-colony stimulating factor priming regimen on a mouse leukemia model

JINQIU CHEN, NAN YANG, HAILING LIU, HUAN YAO, JIN WANG, YUN YANG and WANGGANG ZHANG

Department of Clinical Hematology, Second Affiliated Hospital, Medical School of Xi’an Jiaotong University, Xi’an, Shaanxi 710004, P.R. China

Received October 9, 2017; Accepted April 9, 2018

DOI: 10.3892/ol.2018.9018

Abstract. The low-dose cytarabine, aclarubicin and granulocyte-colony stimulating factor (G-CSF) (CAG) priming regimen is an effective treatment for patients with relapsed or refractory acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS). G-CSF influences the bone marrow microenvironment (BMM) by mobilizing regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), as well as by reducing the expression of stromal cell-derived factor-1α (SDF-1α). In the present study, a WEHI-3-grafted BALB/c mouse AML model (AML-M4) was employed to determine how the BMM was altered by different treatment regimens. It was evident that CAG regimen decreased and increased the proportion of Tregs and MDSCs in the bone marrow and spleen, respectively. Furthermore, the CAG regimen downregulated SDF-1α levels in the bone marrow and peripheral blood. However, hematoxylin and eosin staining of the main organs revealed that leukemic cells infiltrated the liver following treatment with the CAG regimen. The present study indicates that the CAG regimen has a positive effect on the immunosuppressive microenvironment in AML and relieves AML-associated BMM immune suppression by decreasing Tregs and MDSCs in the bone marrow and downregulating the SDF-1α/CXCR4 axis in the bone marrow and peripheral blood.

Introduction

Acute myeloid leukemia (AML), which is a clonal disorder of the myeloid line of blood cells, progresses rapidly and is associated with poor clinical prognosis (1). AML most commonly affects older adults, with a median age at diagnosis of 67 years, and 1/3 AML patients are >75 years old (1). The ‘3+7’ regimen (3 days of anthracycline and 7 days of cytarabine treatment) has remained unchanged for >30 years, and has a 60-80% complete response (CR) rate in adult patients with AML <60 years old, and a 40-60% CR rate in patients >60 years old. The overall curative rate of conventional chemotherapy is only 30-40% in patients <60 years old, and <10% in elderly patients or those with adverse karyotypes (2,3). Patients who experience relapsed or refractory AML, are associated with poor outcomes (3).

The low-dose cytarabine, aclarubicin and granulocyte-colony stimulating factor (G-CSF) (CAG) priming regimen was first developed by Yamada et al (4) for the treatment of relapsed AML in 1995. CAG chemotherapy has since been investigated as an effective treatment for patients with relapsed or refractory AML and advanced myelodysplastic syndrome (MDS) in Japan and China (5-9). The rationale for this regimen is that G-CSF potentiates the anti-leukemic effect of cytosine arabinoside (AraC) (10-12) by recruiting quiescent G0 leukemic cells into the cell cycle (11), thus improving the CR rate of patients with refractory and relapsed leukemia.

Hematopoietic stem cells (HSCs) exist within the niche of the bone marrow microenvironment (BMM) which regulates stem cell survival, proliferation, differentiation and apoptosis (13). The stromal-derived factor-1α (SDF-1α)/C-X-C chemokine receptor type 4 (CXCR4) axis is the key factor associated with HSC chemotaxis (14-16), homing (17,18) and survival/anti-apoptosis (19,20). It has also been demonstrated to dynamically mediate HSC-traffic in the bone marrow (18). Inhibition of the SDF-1α/CXCR4 axis using the CXCR4 antagonist, AMD3100, has been indicated to induce leukemia cells to enter the peripheral circulation and induce higher sensitivity to chemotherapeutic drugs (21). G-CSF, an effective stem cell-mobilizing agent, induces SDF-1α secretion from bone marrow stromal cells into the blood, thus recruiting CXCR4+ cells, including HSCs, into the peripheral circulation (22). It has been established that G-CSF can promote the expression of transcriptional repressor growth factor independence-1 (Gfi-1), which binds to DNA sequences upstream of the CXCR4 gene and reduces CXCR4 expression in myeloid cells (23).
It has been demonstrated that the BMM serves a crucial role in leukemia development and progression, and that it becomes immunosuppressive. Several types of immunosuppressive cells, including regulatory T cells (Tregs) (24), myeloid-derived suppressor cells (MDSCs) (25) and tumor-associated macrophages (TAMs) (26), contribute to the immunologically permissive microenvironment and aid in tumor immune evasion. Tregs and MDSCs mediate their suppressive effects and promote tumor progression by inhibiting T-cell priming (24,25). Furthermore, they provide a favorable microenvironment in which cancer cells can proliferate, expand and evade host immunosurveillance (24,25). As previously reported, SDF-1α is involved in the chemotaxis and adhesion of Tregs and HSCs (27,28). G-CSF can mobilize Tregs from the bone marrow into the peripheral blood by reducing bone marrow-derived SDF-1α expression (27). G-CSF has been identified as a major factor in the differentiation of granulocytic MDSCs (gMDSCs), and tumor-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) has been demonstrated to serve a key role in monocytic MDSC production (29-31).

The present study examined the alteration of the immunosuppressive BMM following administration of G-CSF in combination with low-dose chemotherapy. An established syngeneic leukemia mouse model using the murine AML WEHI-3 cell line (32,33) was used to determine whether the BMM would be altered in vivo following treatment with the CAG priming regimen.

Materials and methods

Cells and reagents. The murine AML cell line, WEHI-3, was maintained in the laboratory of the Department of Clinical Hematology, Second Affiliated Hospital, Medical School of Xi'an Jiao Tong University (Xi'an, China) in DMEM medium supplemented with 10% fetal bovine serum (Biological Industries, Israel) and 1% penicillin-streptomycin (100 U/ml penicillin and 100 mg/ml streptomycin; cat no. 15140-122; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The following antibodies were used for flow cytometry (FCM): Fluorescein isothiocyanate (FITC) anti-mouse cluster of differentiation (CD)4 (cat no. 11-0042), allopurinol (APC) anti-mouse CD25 (cat no. 17-0251), phycoerythrin (PE) anti-mouse/rat Forheac box P3 (Foxp3) (cat no. 12-5773) and PE anti-mouse CD184 (CXCR4; cat no. 12-9991), and all were purchased from BD Biosciences (San Jose, CA, USA). The mouse SDF-1α (CXCL12) (cat no. 12-9991), and all were purchased from BD Biosciences (San Jose, CA, USA). The following antibodies were used for flow cytometry (FCM): Fluorescein isothiocyanate (FITC) anti-mouse cluster of differentiation (CD)4 (cat no. 11-0042), allopurinol (APC) anti-mouse CD25 (cat no. 17-0251), phycoerythrin (PE) anti-mouse/rat Forheac box P3 (Foxp3) (cat no. 12-5773) and PE anti-mouse CD184 (CXCR4; cat no. 12-9991), and all were purchased from BD Biosciences (San Jose, CA, USA). The mouse SDF-1α (cat no. MCX120), transforming growth factor β (TGF-β; cat no. MB100B) and interleukin 10 (IL-10; cat no. M1000B) ELISA kits were purchased from R&D Systems, Inc. (Minneapolis, MN, USA), and the arginase 1 (Arg-1; cat no. JL13668) ELISA kit was purchased from and Shanghai Jiang Lai Biotechnology Co., Ltd. (Shanghai, China; http://www.laibio.com/).

Leukemia mouse model and chemotherapy regimens. All animal experiments were reviewed and approved by the Ethics Committee of the Medical College, Xi'an Jiao Tong University (Xi'an, China). Male BALB/c wild-type mice (6-8 weeks old, weighed 21±2 g) were purchased from the Laboratory Animal Center, Medical College of Xi'an Jiao Tong University. The mice were maintained under specific pathogen-free conditions, in a 12/12 light/dark cycle at 21±2°C, with access to food and water ad libitum. A total of 21 mice were randomly divided into 3 groups of 7. For the syngeneic acute myelomonocytic leukemia model (AML-M4), BALB/c mice were injected intravenously into the tail vein on day 0 with 1x10^6 WEHI-3 cells in 100 µl PBS as previously described (32-34).

On day 15, all 7 mice in the AML (control) group were humanely sacrificed and the spleen, liver, femur and blood were collected and stored for further experiments. For the daunorubicin and cytarabine (DNRAraC; DA) group, 7 mice were treated with 10 mg/kg DNR intravenously on days 15-17 and 50 mg/kg AraC intraperitoneally on days 15-21. Mice in DA group were sacrificed on day 22 and the spleen, liver, femur and blood were collected for further experiments. For the CAG group, 7 mice were treated with 6.25 mg/kg AraC via hypodermic injection (IH) on days 15-18, 3 mg/kg aclarubicin (ACR) intravenously on days 15-28 and 0.2 mg/kg G-CSF via IH on days 15-28. All mice in CAG group were sacrificed on day 29 and the spleen, liver, femur and blood were collected for further experiments.

ELISA. SDF-1α, IL-10 and Arg-1 levels in the blood plasma were determined using the aforementioned commercially available mouse ELISA kits, according to the manufacturers' protocols. Absorbance was measured at 450 nm on a microplate reader (Thermo Fisher Scientific, Inc.).

FCM analysis. Single-cell suspensions of spleen cells and bone marrow mononuclear cells (BMMCs) were stained with FITC-conjugated anti-mouse CD4 (dilution, 1:100) and APC-conjugated anti-mouse CD25 (dilution, 1:100) for 30 min on ice. The cells were washed with flow cytometry staining buffer (eBioscience; Thermo Fisher Scientific, Inc.), resuspended in 1 mlfixation/permeabilization working solution (eBioscience; Thermo Fisher Scientific, Inc.) and incubated at 4°C, in the dark, overnight. The cells were washed twice with 1X permeabilization buffer (eBioscience; Thermo Fisher Scientific, Inc.) and incubated for 30 min at 4°C in 1X permeabilization buffer containing PE-conjugated anti-mouse Foxp3 (dilution, 1:40) antibody. Forward vs. side scatter was plotted for lymphocytes, followed by gating for CD4+ T cells. These cells were then analyzed for the expression of CD25 and FoxP3. For the detection of MDSCs and CXCR4, single-cell suspensions were stained with CD11b (dilution, 1:200), Gr-1 (Ly-6G and Ly-6C; dilution, 1:200) or CXCR4 (dilution, 1:200) antibodies. FCM was performed using a FACS flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) and the data was analyzed using CellQuest Pro (version 6.0; BD Biosciences).

Pathological examinations. The femur, liver and spleen tissues were harvested and immediately fixed in 10% neutral-buffered formalin for 24 h. Liver and spleen tissues were embedded in paraffin and the femurs were decalcified in 10% EDTA for ~30 days at room temperature prior to being embedded in paraffin. A total of 54-µm-thick sections were cut from each paraffin block. The sections were stained at room 25°C using hematoxylin (H) for 6 min and eosin (E) for 1 min (cat no. C0105; Beyotime Institute of Biotechnology, Shanghai, China),
according to standard histochemical procedures. Images were acquired using a light microscope (DP71; Olympus Corporation, Tokyo, Japan).

**Statistical analysis.** All data are expressed as the mean ± standard deviation. Differences between treatment groups were determined using analysis of variance followed by Fisher’s Least Significant Difference post-hoc test. P<0.05 was considered to indicate a statistically significant difference. All analyses were performed using SPSS 18.0 software (SPSS Inc., Chicago, IL, USA).

**Results**

**CAG treatment regimen decreases the number of Tregs and MDSCs in bone marrow.** To determine whether the CAG and DA treatment regimens affect AML immunosuppressive cells in the BMM, FCM was performed to investigate the percentage of CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> Tregs and CD11b<sup>+</sup>Gr-1<sup>+</sup> MDSCs in BMMCs. It was revealed that the levels of Tregs and MDSCs in the DA and CAG groups were significantly lower than in the AML group (P<0.01; Fig. 1A). Furthermore, compared with mice in the DA group, mice in CAG group exhibited significantly decreased levels of Tregs and MDSCs in BMMCs (P<0.05; Fig. 1A).

**CAG treatment regimen decreases Tregs and MDSCs associated cytokine levels in the BMM.** TGF-β and IL-10 are anti-inflammatory and immunosuppressive cytokines secreted by Tregs (35,36), while Arg-1, which suppresses T-lymphocyte function, is expressed by MDSCs (37,38). The ELISA results demonstrated that the concentrations of TGF-β1, IL-10 and Arg-1 in the bone marrow supernatant were significantly decreased in the DA (P<0.01) and CAG (P<0.01) groups compared with the AML group (Fig. 1B). The CAG group exhibited lower TGF-β1 (P<0.01), IL-10 (P<0.01) and Arg-1 (P<0.05) concentrations compared with the DA group (Fig. 1B). These results suggest that the CAG treatment regimen may rescue immune suppression in AML bone marrow.

**Compared with the DA treatment regimen, the CAG treatment regimen increases Treg and MDSC numbers in the spleen.** The percentages of Tregs and MDSCs in mice spleen single cell suspensions were tested by FCM. As shown in Fig. 2, mice in the DA and CAG groups both exhibited lower percentages of Tregs and MDSCs in spleen than AML group (P<0.01). However, there were significantly higher levels of Tregs (P<0.01) and MDSCs (P<0.05) in the CAG group than the DA group.

**CAG treatment regimen downregulates SDF-1α levels in the bone marrow.** The level of SDF-1α in bone marrow supernatant was detected by ELISA, and the results revealed that the concentration of SDF-1α in the CAG group was significantly lower than the AML and DA groups (P<0.01). However, there was no significant difference (in the concentration of bone marrow SDF-1α between AML and DA groups (P>0.05; Fig. 3).
CAG treatment regimen reduces SDF-1α levels in the peripheral blood. ELISA results demonstrated that the CAG group exhibited the lowest levels of SDF-1α in the peripheral blood among the 3 groups of mice (Fig. 4). In consistence with the concentration of SDF-1α in the bone marrow, there was no significant difference in the concentration of SDF-1α in the peripheral blood between the AML and DA groups (P>0.05).

Histopathology of the femur, liver, and spleen tissues. Macroscopically, the femurs of AML mice were pale (Fig. 5Aa) and the liver and spleen were swollen (Fig. 5Ab and c) compared with the DA and CAG mice. The DA (Fig. 5Ba) and CAG (Fig. 5Ca) treatment regimens reddened the femurs and decreased the size of the liver and spleen (Fig. 5Bb and c). Leukemic cells in the bone marrow cavity of mice from the AML group were visible under the light microscope (Fig. 6Aa). By contrast, the femur sections from mice of the DA and CAG groups exhibited a recovered hematopoietic system (Fig. 6Ba and Ca). In AML mice, leukemic cells infiltrated the liver and spleen (Fig. 6Ab and c). However, in the DA group, fewer leukemic cells infiltrated the liver and spleen and the pathological sections exhibited liver fibrosis and spleen trabecula fibrosis (Fig. 6Bb and c). In the CAG group, leukemic cells infiltrated the hepatic portal and central veins (Fig. 6Cb) indicated by the arrows. In the spleens, the boundary of red pulp widened and the white pulp was clear (Fig. 6Cc).

Discussion

G-CSF has been widely used in the treatment of refractory and relapsed AML together with chemotherapeutic drugs, and has improved the CR rate (13). Although it is well-established that G-CSF has an important influence on the BMM (22), there is little research regarding the effect of G-CSF priming chemotherapy on the BMM. G-CSF can promote leukemia cells to be released from the bone marrow into the peripheral circulation by blocking the interaction of SDF-1α and CXCR4, thus enhancing the anti-leukemia effect (13). G-CSF also mobilizes immunosuppressive Tregs from the bone marrow into the peripheral blood (27). We hypothesize that there is an effect of the G-CSF priming regimen on the BMM in AML.

An AML-M4 BALB/c mouse model was established to study the BMM in vivo in mice receiving different chemotherapy regimens. Changes in the SDF-1α/CXCR4 axis,
Tregs, MDSCs and associated cytokines were investigated. In accordance with previous studies, it was demonstrated that the CAG regimen had a positive effect on the immunosuppressive microenvironment in AML.
In the AML-M4 BALB/c mouse model, the number of Tregs and MDSCs in the bone marrow decreased following CAG chemotherapy. The concentrations of immunosuppressive cytokines (TGF-β1, IL-10 and Arg-1), secreted by Tregs and MDSCs, were lower in the CAG group compared with the DA group. The number of Tregs and MDSCs in the spleen, the largest immune organ, was high. This suggests that G-CSF may mobilize Tregs and MDSCs from the bone marrow to the periphery, and that the G-CSF priming regimen may relieve AML-associated BMM immune suppression by reducing the number of MDSCs and Tregs in the bone marrow. This may help to explain how G-CSF administration reduces the severity of acute graft-vs-host disease (GVHD) (27).

The BMM provides a protective niche for HSCs (28) and it is the primary site of minimal residual disease (MRD) following chemotherapy (39). By hijacking the HSC niche (40), leukemia stem cells (LSCs) in the bone marrow niche serve roles in leukemia initiation, maintenance and recurrence (41). G-CSF priming chemotherapy treatment significantly increased LSC apoptosis and increases responsiveness to chemotherapy in vivo by modifying the functional behavior of LSCs (42). On the other hand, G-CSF inhibits the interaction of SDF-1α and CXCR4, thus reducing LSC migration to the BMM, which involves CXCR4 (43). In the present study, it was also demonstrated that mice in the CAG group expressed the lowest level of SDF-1α in the bone marrow and peripheral blood, which indicates that the SDF-1α/CXCR4 axis may have been downregulated in the CAG treatment regimen.

However, the CAG treatment regimen is limited in that there were more residual leukemic cells subsequent to treatment in the livers of the CAG mice than the DA mice. This may result from the low dose of the chemotherapeutic agents, AraC and ACR. However, the low doses used in the CAG regimen result in less severe clinical side-effects than common induction chemotherapy, such as the DA regimen. Due to its milder toxicity and a short duration of G-CSF neutropenia treatment, the CAG regimen is suitable for elderly patients (5,44,45).

The present study suggests that the CAG leukemia treatment regimen has a positive effect on the immunosuppressive microenvironment in AML and relieves AML-associated BMM immune suppression by decreasing the number of Tregs and MDSCs in the bone marrow. The results indicate that downregulation of the SDF-1α/CXCR4 axis in the bone marrow and peripheral blood is caused by CAG chemotherapy. The lower dose of chemotherapeutic agents in the CAG regimen leads to milder side-effects but more residual leukemic cells. Overall, the CAG regimen relieves immune suppression in the leukemic BMM and is suitable for elderly patients.

Acknowledgments

Not applicable.

Funding

The present study was supported by the National Natural Science Foundation of China (grant no. 81270597).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

JC performed the murine model and chemotherapy regimens, performed the majority of the experiments and was a major contributor in writing the manuscript. NY performed FCM, analyzed the FCM data and helped in writing the manuscript. HL and HY sacrificed all the mice and harvested the organs and pretreated them. JW performed pathological examinations and acquired data of these experiments. YY performed ELISA and acquired data of this experiment. WZ designed the study, revised the manuscript and gave final approval of the version to be published. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All animal experiments were reviewed and approved by the Ethics Committee of the Medical College, Xi’an Jiaotong University (Xi’an, China).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Podoltsev NA, Stahl M, Zeidan AM and Gore SD: Selecting initial treatment of acute myeloid leukaemia in older adults. Blood Rev 31: 43-62, 2017.
2. Döhner H, Weisdorf DJ and Bloomfield CD: Acute myeloid leukemia. N Engl J Med 373: 1136-1152, 2015.
3. Döhner H, Éstey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, et al: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115: 453-474, 2010.
4. Yamada K, Furusawa S, Saito K, Waga K, Koike T, Arimura H, Aoyagi A, Yamato H, Sakuma H, Tsunogake S, et al: Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclacinobin for previously treated acute myelogenous leukaemia: A pilot study. Leukemia 9: 10-14, 1995.
5. Minakata D, Fujiwara S, Ito S, Mashima K, Umino K, Nakano H, Kawasaki Y, Sugimoto M, Yamasaki R, Yamamoto C, et al: A low-dose cytarabine, aclacinobin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukaemia: A propensity score analysis. Leuk Res 42: 82-87, 2016.
6. Jin J, Chen J, Suo S, Qian W, Meng H, Mai W, Tong H, Huang J, Yu W, Wei J and Lou Y: Low-dose cytarabine, aclacinobin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukaemia. Leuk Lymphoma 56: 1691-1697, 2015.
7. Wang Y, Li W, Chen S, Qiu H, Sun A and Wu D: Salvage chemotherapy with low-dose cytarabine and aclacinobin in combination with granulocyte colony-stimulating factor priming in patients with refractory or relapsed acute myeloid leukaemia with translocation (8;21). Leuk Res 35: 604-607, 2011.
and GM-CSF

and Tumor-derived granulocyte-macrophage

Targeting the

A

and Transgenic expression of stromal

+ 

15.

20.

19.

26.

20.

18.

3028

30.

28.

30.

27.

28.

27.

26.

25.

24.

23.

22.

21.

20.

19.

18.

17.

16.

15.

14.

13.

12.

11.

10.

9.

8.

7.

6.

5.

4.

3.

2.

1.

8

16

24

32

40

48

56

64

72

80

88

96

104

112

120

128

136

144

152

160

168

176

184

192

196

198

200

202

204

206

208

210

212

214

216

218

220

222

224

226

228

230

232

234

236

238

240

242

244

246

248

250

252

254

256

258

260

262

264

266

268

270

272

274

276

278

280

282

284

286

288

290

292

294

296

298

300

302

304

306

308

310

312

314

316

318

320

322

324

326

328

330

332

334

336

338

340

342

344

346

348

350

352

354

356

358

360

362

364

366

368

370

372

374

376

378

380

382

384

386

388

390

392

394

396

398

400

402

404

406

408

410

412

414

416

418

420

422

424

426

428

430

432

434

436

438

440

442

444

446

448

450

452

454

456

458

460

462

464

466

468

470

472

474

476

478

480

482

484

486

488

490

492

494

496

498

500

502

504

506

508

510

512

514

516

518

520

522

524

526

528

530

532

534

536

538

540

542

544

546

548

550

552

554

556

558

560

562

564

566

568

570

572

574

576

578

580

582

584

586

588

590

592

594

596

598

600

602

604

606

608

610

612

614

616

618

620

622

624

626

628

630

632

634

636

638

640

642

644

646

648

650

652

654

656

658

660

662

664

666

668

670

672

674

676

678

680

682

684

686

688

690

692

694

696

698

700

702

704

706

708

710

712

714

716

718

720

722

724

726

728

730

732

734

736

738

740

742

744

746

748

750

752

754

756

758

760

762

764

766

768

770

772

774

776

778

780

782

784

786

788

790

792

794

796

798

800

802

804

806

808

810

812

814

816

818

820

822

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.